Somaxon unveils $86.2M IPO
San Diego-based Somaxon Pharmaceuticals has filed to sell $86.2 million of stock in an upcoming IPO. Much of that money is earmarked for three drug development projects. Somaxon is advancing drug candidates for psychiatry and neurology. Morgan Stanley, JPMorgan, Piper Jaffray and Thomas Weisel Partners are listed as underwriters.
- read this Dow Jones report for more
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
